Pyrrole Derivative Acid Blockade for Stable Proton Pump Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing proton pump inhibitors are unstable under acidic conditions and show inconsistent treatment effects due to metabolic enzyme polymorphism and drug interactions, leading to suboptimal performance in suppressing gastric acid secretion for peptic ulcer and reflux esophagitis treatment.

Innovation Solution

A compound represented by the formula (I) with a monocyclic nitrogen-containing heterocyclic group, optionally condensed with a benzene ring or heterocycle, exhibits a strong proton pump inhibitory effect by reversibly inhibiting H+/K+-ATPase activity, providing a potassium-competitive acid blockade.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If existing proton pump inhibitors are formulated as enteric preparations to improve stability under acidic conditions, then stability is improved, but several hours are required before expression of the effect

Engineering Contradiction:

Improvestability under acidic conditionsVSAvoidtime required before effect expression

Core Design Contradiction:

Stability of the object's compositionVSLoss of time

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of proton pump inhibitors to change their stability parameters. The compounds of formula (I) possess improved acid stability as an inherent molecular property, eliminating the need for enteric coating while enabling rapid onset. This structural parameter change resolves the contradiction between stability and rapid effect expression.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing proton pump inhibitors are used, then acid secretion suppression is achieved, but inconsistent treatment effects occur due to metabolic enzyme polymorphism and drug interaction

Engineering Contradiction:

Improvetreatment effect consistencyVSAvoidmetabolic enzyme polymorphism and drug interaction

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent employs a reversible binding mechanism where the inhibitor binds to the proton pump and then dissociates, allowing the enzyme to regenerate and be reused. This reversible interaction avoids permanent modification of the enzyme, reducing variability from metabolic polymorphism and drug interactions, thereby improving treatment consistency.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If existing proton pump inhibitors form covalent bonds with H+/K+-ATPase to irreversibly inhibit enzyme activity, then strong acid secretion suppression is achieved, but instability under acidic conditions and drug interactions occur

Engineering Contradiction:

Improveacid secretion suppression efficacyVSAvoidstability under acidic conditions

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

Instead of using irreversible covalent bonding as the mechanism for strong inhibition, the patent inverts the approach by using reversible non-covalent binding. This inversion maintains effective acid secretion suppression through potent reversible inhibition while eliminating the instability and interaction problems associated with irreversible binding and enteric coating requirements.

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compound effectively suppresses gastric acid secretion, offering a superior treatment for peptic ulcers, reflux esophagitis, and other gastrointestinal disorders with rapid symptom relief and improved stability under acidic conditions, allowing for oral administration without enteric coating.

Implementation Method 1

since compound (I) inhibits the proton pump (H+/K+-ATPase) activity reversibly and in a K+ antagonist inhibitory manner

Methodology Applied

Scientific EffectReversible inhibition:

Implementation Method 2

in a K+ antagonist inhibitory manner to consequently suppress acid secretion

Methodology Applied

Scientific EffectPotassium competition:

Data Source

PatentEP2327692B91-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors

Publication Date: 2014.06.04 TAKEDA PHARMA CO LTD

AI summary

A compound represented by the formula (I): wherein R1 is a monocyclic nitrogen-containing heterocyclic group optionally condensed with a benzene ring or a heterocycle, the monocyclic nitrogen-containing heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R3 and R4 are each a hydrogen atom, or one of R3 and R4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R5 is an alkyl group, or a salt thereof, for use for the treatment or prophylaxis of peptic ulcer, Zollinger-Ellison syndrome, gastritis, erosive esophagitis, reflux esophagitis, symptomatic gastroesophageal reflux disease (Symptomatic GERD), functional dyspepsia, gastric cancer, stomach MALT lymphoma, or gastric hyperacidity; or the inhibition of upper gastrointestinal hemorrhage due to peptic ulcer, acute stress ulcer, hemorrhagic gastritis or invasive stress, or for use for the eradication of helicobacter pylori.